View Cart (0 items)

Pharmaceutical

FDA seeks to ban dietary supplements unlawfully marketed as drugs

The U.S. Food and Drug Administration has taken administrative action against a dietary supplement manufacturer following multiple breaches of the Federal Food, Drug and Cosmetic Act.
Read More

Generics dent market share of brand-name drugs

The growth of the generic drug market worldwide may turn out to be a long-term trend, experts say, as a number of studies show a stable decline in prescriptions of brand-name drugs last year.
Read More

FDA publishes finalized guidance on medical apps

The FDA will not be regulating the majority of medical apps because they pose very little health risk to patients, but will instead adopt a "risk-based approach."
Read More

FDA tightens grip on Indian drug makers

The U.S. Food and Drug Administration (FDA) has warned two Indian pharmaceutical companies over suspected breaches of good manufacturing practices.
Read More

FDA reiterates warning over NuVision's sterile products

The U.S. Food and Drug Administration (FDA) has issued another alert over sterile products manufactured by Dallas-based NuVision Pharmacy.
Read More

GlaxoSmithKline sets up $50 million fund to develop bioelectronic medicines

UK-based GlaxoSmithKline, one of the biggest pharmaceutical companies on the planet, wants to be a leader in the bioelectronic medicines space.
Read More

Chinese pharma probe spreads to two Danish drug makers

Western pharmaceutical companies are coming under increased scrutiny in China following the bribery accusations leveled last month against GlaxoSmithKline (GSK).
Read More

Generic drug patent settlements cut costs for health systems, study finds

The U.S. health system saved a total of $25.5 billion between 2005 and 2012 thanks to generic drugs being launched on the market before patent expirations as a result of patent settlements.
Read More

FDA bans production at New Jersey compound firm over sterility issues

The U.S. Food and Drug Administration (FDA) has taken action against New Jersey-based compounding pharmacy Med Prep Consulting, Inc. over concerns relating to the sterility of its production.
Read More

King Pharmaceuticals to pay $2.2 million over Clean Air Act violations

Tennessee-based King Pharmaceuticals, a subsidiary of Pfizer, Inc., will pay a $2.2. million penalty to resolve issues relating to allegations of Clean Air Act violations, the U.S. Environmental Protection Agency (EPA) announced.
Read More